Skip to main content
NTHI
NASDAQ Life Sciences

NEONC Technologies Secures UAE IND Approval for NEO212, Advancing to Global Phase 2 Trials

Analysis by Wiseek AI
Sentiment info
Positive
Importance info
8
Price
$5.17
Mkt Cap
$137.089M
52W Low
$3.2
52W High
$12.99
Market data snapshot near publication time

Summary

NEONC Technologies received IND approval from Abu Dhabi for its brain tumor therapy NEO212, enabling Phase 2 clinical trials in the UAE and establishing a new international development pathway.


Key Events

  • UAE IND Approval for NEO212

    The Department of Health – Abu Dhabi (DOH) granted Investigational New Drug (IND) status for NEO212, an orally administered perillyl alcohol-temozolomide carbamate conjugate for aggressive brain tumors.

  • Advancing to Phase 2 Clinical Trials

    This clearance enables the company to proceed with Phase 2 clinical development of NEO212 in the United Arab Emirates, following the successful completion of its Phase 1 dose-escalation study.

  • Global Development Strategy

    The approval establishes an international clinical pathway, complementing ongoing discussions with the U.S. FDA for a potential registrational pathway and potentially accelerating overall drug development.

  • NEO100 Programs Submitted

    The company has also submitted applications for its NEO100 clinical programs (NEO100-01, NEO100-02, and NEO100-03) to the DOH – Abu Dhabi, with regulatory decisions currently pending.


Analysis

This 8-K announces a significant regulatory milestone for NEONC Technologies, a clinical-stage biopharmaceutical company. The Investigational New Drug (IND) status granted by Abu Dhabi's Department of Health for NEO212 allows the company to advance its lead brain tumor therapy into Phase 2 clinical trials in the UAE. This development is crucial for a company that has recently disclosed going concern warnings and is actively raising capital, as it validates the drug candidate and expands its potential development pathways, which can attract further investment and extend its operational runway.

At the time of this filing, NTHI was trading at $5.17 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $137.1M. The 52-week trading range was $3.20 to $12.99. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

NTHI - Latest Insights

NTHI
Jun 18, 2026, 5:00 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $5.17
Real-time Price: $5.17 info
Change: $0 (0%) info
Market Cap: $137.089M info
NTHI
Jun 16, 2026, 9:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $5.09
Real-time Price: $5.17 info
Change: +$0.080 (+2%) info
Market Cap: $137.089M info
NTHI
Jun 15, 2026, 4:24 PM EDT
Filing Type: S-3
Importance Score:
8
Price at Filing: $4.51
Real-time Price: $5.17 info
Change: +$0.660 (+15%) info
Market Cap: $137.089M info
NTHI
Jun 12, 2026, 6:06 AM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $4.88
Real-time Price: $5.17 info
Change: +$0.290 (+6%) info
Market Cap: $137.089M info
NTHI
Jun 12, 2026, 6:01 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $4.88
Real-time Price: $5.17 info
Change: +$0.290 (+6%) info
Market Cap: $137.089M info
NTHI
Jun 11, 2026, 4:15 PM EDT
Filing Type: PRE 14A
Importance Score:
9
Price at Filing: $4.50
Real-time Price: $5.17 info
Change: +$0.670 (+15%) info
Market Cap: $137.089M info
NTHI
May 18, 2026, 5:00 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $5.34
Real-time Price: $5.17 info
Change: -$0.170 (-3%) info
Market Cap: $137.089M info
NTHI
May 18, 2026, 9:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $5.40
Real-time Price: $5.17 info
Change: -$0.230 (-4%) info
Market Cap: $137.089M info
NTHI
May 15, 2026, 4:32 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $5.50
Real-time Price: $5.17 info
Change: -$0.330 (-6%) info
Market Cap: $137.089M info
NTHI
May 04, 2026, 9:41 PM EDT
Filing Type: 10-K/A
Importance Score:
8
Price at Filing: $4.20
Real-time Price: $5.17 info
Change: +$0.970 (+23%) info
Market Cap: $137.089M info